advertisement

WGA Rescources

Zou Y 8

Showing records 1 to 8 | Display all abstracts from Zou Y

117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Qu S
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Yang M
International journal of molecular sciences 2024; 25:
117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Qu S
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Kamoi K
International journal of molecular sciences 2024; 25:
117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Zou Y
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Zong Y
International journal of molecular sciences 2024; 25:
117292 The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
Yang L; Wu H
Frontiers in medicine 2023; 10: 1280776
118115 Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis
Zhang J; Zou Y; Ohno-Matsui K
International journal of molecular sciences 2024; 25:

Issue 24-4

Change Issue


advertisement

WGA Rescources